USFDA inspection at Zydus' formulation manufacturing facility at SEZ 2, Ahmedabad concludes with nil observations

Zydus Lifesciences Ltd., today announced that the group's manufacturing facility at SEZ-2 located at Pharmez, Ahmedabad, underwent a USFDA inspection from 2nd July to 7th July, 2023. The Pre-Approval Inspection (PAI) closed with nil observations.

Shares of Cadila Healthcare Limited was last trading in BSE at Rs. 582.75 as compared to the previous close of Rs. 587.20. The total number of shares traded during the day was 19705 in over 1328 trades.

The stock hit an intraday high of Rs. 589.30 and intraday low of 580.40. The net turnover during the day was Rs. 11519078.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 USFDA Inspection NilObservations